STOCK TITAN

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags

TransMedics (Nasdaq: TMDX) on October 27, 2025 granted inducement equity awards to 15 new employees under Nasdaq Listing Rule 5635(c)(4) and the TransMedics Inducement Plan. The company granted non-qualified stock options to purchase an aggregate of 27,582 shares and 18,299 restricted stock units.

Options carry a $132.45 per-share exercise price (closing price on October 27, 2025), a 10-year term, and vest 25% after one year with the remainder vesting monthly over the next three years. RSUs vest 25% on each of the first four anniversaries of employment, each subject to continued service and plan terms.

TransMedics (Nasdaq: TMDX) il 27 ottobre 2025 ha concesso premi azionari di inducement a 15 nuovi dipendenti ai sensi della Nasdaq Listing Rule 5635(c)(4) e del TransMedics Inducement Plan. L'azienda ha concesso opzioni su azioni non qualificate per l'acquisto di un totale di 27.582 azioni e 18.299 unità di azioni vincolate.

Le opzioni hanno un prezzo di esercizio per azione di 132,45 USD (prezzo di chiusura del 27 ottobre 2025), una durata di 10 anni e si vestono al 25% dopo un anno, con il restante vesting mensile nei tre anni successivi. Le RSU vestiscono al 25% in ciascuno dei primi quattro anniversari dell'impiego, soggette a servizio continuato e ai termini del piano.

TransMedics (Nasdaq: TMDX) el 27 de octubre de 2025 concedió premios de acciones por inducimiento a 15 nuevos empleados bajo la Regla de Listado Nasdaq 5635(c)(4) y el Plan de Inducción de TransMedics. La empresa otorgó opciones de compra de acciones no calificadas para comprar un total de 27,582 acciones y 18,299 unidades de acciones restringidas.

Las opciones tienen un precio de ejercicio por acción de $132.45 (precio de cierre del 27 de octubre de 2025), un plazo de 10 años, y se adquieren en un 25% después de un año con el resto vesting mensualmente durante los próximos tres años. Las RSU se consolidan en un 25% en cada uno de los cuatro aniversarios de empleo, sujetas a continuidad del servicio y a los términos del plan.

TransMedics (Nasdaq: TMDX) 2025년 10월 27일 Nasdaq Listing Rule 5635(c)(4) 및 TransMedics Inducement Plan에 따라 15명의 신규 직원에게 유인 주식 보상을 부여했습니다. 회사는 27,582주를 매수할 수 있는 비적격 주식 옵션과 18,299개의 제한 주식 단위를 부여했습니다.

옵션의 주당 행사 가격은 $132.45로(2025년 10월 27일 종가), 기간은 10년이며 1년 후 25%가 vesting되고 남은 부분은 향후 3년 동안 매월 vesting됩니다. RSU는 고용의 각 첫 4주년 중 매년 25% vesting되며, 지속적인 서비스 및 계획 조항의 적용을 받습니다.

TransMedics (Nasdaq: TMDX) a accordé le 27 octobre 2025 des attributions d'actions d'induction à 15 nouveaux employés conformément à la règle de cotation Nasdaq 5635(c)(4) et au TransMedics Inducement Plan. L'entreprise a octroyé des options d'achat d'actions non qualifiées pour acheter un total de 27 582 actions et 18 299 unités d'actions restreintes.

Les options ont un prix d'exercice par action de 132,45 $ (cours de clôture du 27 octobre 2025), une durée de 10 ans, et se vestent à 25% après un an avec le restant vesting mensuellement sur les trois années suivantes. Les RSU se vestent à 25% à chacun des quatre premiers anniversaires de l'emploi, sous réserve d'un service continu et des termes du plan.

TransMedics (Nasdaq: TMDX) hat am 27. Oktober 2025 Inducement-Aktienzertifikate an 15 neue Mitarbeiter gemäß Nasdaq Listing Rule 5635(c)(4) und dem TransMedics Inducement Plan gewährt. Das Unternehmen gewährte nicht qualifizierte Aktienoptionen zum Kauf insgesamt 27.582 Aktien und 18.299 Restricted Stock Units.

Optionen haben einen Ausübungspreis pro Aktie von 132,45 $ (Schlusskurs am 27. Oktober 2025), eine Laufzeit von 10 Jahren und vesten zu 25% nach einem Jahr, der Rest vestet monatlich über die nächsten drei Jahre. RSUs vesten zu 25% an jedem der ersten vier Jahrestage der Beschäftigung, jeweils vorbehaltlich fortgesetztem Dienstverhältnis und Planbedingungen.

TransMedics (Nasdaq: TMDX) في 27 أكتوبر 2025 منحت جوائز أسهم استثنائية (inducement) لـ15 موظفًا جديدًا بموجب قاعدة الإدراج Nasdaq 5635(c)(4) وخطة Inducement الخاصة بـ TransMedics. منحت الشركة خيارات شراء أسهم غير مؤهلة لشراء إجمالي 27,582 سهمًا و< b>18,299 وحدة أسهم مقيدة.

تحمل الخيارات سعر ممارسة للسهم قدره $132.45 (سعر الإغلاق في 27 أكتوبر 2025)، ومدى 10 سنوات، وتتحقق الملكية بنسبة 25% بعد عام واحد مع تحقق الباقي شهريًا على مدى الأعوام الثلاثة التالية. تتحقق RSUs بنسبة 25% في كل واحد من anniversaries الأربعة الأولى للتوظيف، مع خضوعها لاستمرار الخدمة وشروط الخطة.

Positive
  • None.
Negative
  • None.

ANDOVER, Mass., Oct. 31, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on October 27, 2025, TransMedics granted non-qualified stock options to purchase an aggregate of 27,582 shares of its common stock and an aggregate of 18,299 restricted stock units to 15 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the TransMedics Group, Inc. Inducement Plan.

TransMedics granted non-qualified stock options to purchase 27,582 shares of TransMedics' common stock and 18,299 restricted stock units in the aggregate. The stock options were granted with a per share exercise price of $132.45, the closing price of the common stock on the Nasdaq Global Market on October 27, 2025. Twenty-five percent of the shares subject to each option will vest on the first yearly anniversary of the date of the employee's start of employment, with the remainder vesting in equal monthly installments over the subsequent three year period, subject to the employee's continued service with the company through the applicable vesting date. The options have a 10-year term and are subject to the terms of the TransMedics Group, Inc. Inducement Plan. Twenty-five percent of each restricted stock unit award will vest on the first four anniversaries of the date of the employee's start of employment, subject to the employee's continued service with the company through the applicable vesting date. The restricted stock units are subject to the terms of the TransMedics Group, Inc. Inducement Plan.

About TransMedics Group, Inc.

TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact:
Brian Johnston
Laine Morgan
332-895-3222
Investors@transmedics.com 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/transmedics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302601162.html

SOURCE TransMedics Group, Inc.

FAQ

What equity inducement did TransMedics (TMDX) grant on October 27, 2025?

TransMedics granted an aggregate of 27,582 non-qualified stock options and 18,299 restricted stock units to 15 employees as inducement awards.

What exercise price and term apply to the TransMedics (TMDX) options granted October 27, 2025?

The options have a per-share exercise price of $132.45 and a 10-year term.

How do the TransMedics (TMDX) option vesting schedules work for the October 27, 2025 grants?

Options vest 25% on the first anniversary of employment, with the remainder vesting in equal monthly installments over the next three years, subject to continued service.

What is the vesting schedule for the TransMedics (TMDX) restricted stock units granted October 27, 2025?

Each RSU award vests 25% on each of the first four anniversaries of the employee's start date, subject to continued service and plan terms.

Under what rule and plan were TransMedics (TMDX) inducement awards granted on October 27, 2025?

The awards were approved under Nasdaq Listing Rule 5635(c)(4) and granted pursuant to the TransMedics Group, Inc. Inducement Plan.

How many employees received inducement awards from TransMedics (TMDX) on October 27, 2025?

Fifteen employees received the inducement stock option and RSU grants.
Transmedics Group

NASDAQ:TMDX

TMDX Rankings

TMDX Latest News

TMDX Latest SEC Filings

TMDX Stock Data

4.64B
33.17M
3.01%
111.49%
24.26%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
ANDOVER